Clinical Trial Update: CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults [Phase 3]

View source ↗

Summary

Phase 3 trial of CONCERTA (OROS methylphenidate hydrochloride) for attention-deficit/hyperactivity disorder in adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• CONCERTA (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Janssen-Ortho Inc., Canada | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED